Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes

American Journal of Health-System Pharmacy

Volumn 55, Issue 24 SUPPL., 1998, Pages

  Brown, Ronald R ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; BLOOD PRESSURE; BODY WEIGHT; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DRUG COST; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0032534881     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.suppl_4.s24     Document Type: Conference Paper

References (14)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 319:977-86.
2. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized, prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17.
3. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetics. Arch Intern Med. 1998; 158:134-40.
4. Dornan TL, Heller SR, Peck GM et al. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care. 1991; 14:342-4.
5. Hollonbeck CB, Johnson P, Varasteh BB et al. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridemia and non-insulin-dependent diabetes by glucose tolerance test criteria. Diabete Metab. 1991; 17:483-9.
6. Teupe B, Bergis K. Prospective, randomized two-year clinical study comparing additional metformin with reducing diet in type 2 diabetes. Diabete Metab. 1991; 17:213-7.
7. Campbell IW, Menzies DG, Chalmers J et al. One-year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab. 1994; 21:394-400.
8. Hermann LS, Schersten B, Bitzen P-O et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind, controlled study. Diabetes Care. 1994; 17:1100-9.
9. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS 13): relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ. 1995; 310:83-8.
10. Defronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333:541-9.
11. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled on diet therapy. Ann Intern Med. 1998; 128:165-75.
12. Haupt E, Knick B, Koschinsky T et al. Oral antidiabetic combination therapy with sulfonylureas and metformin. Diabete Metab. 1991; 17:224-31.
13. Hermann LS, Schersten B, Melander A. Antihyperglycemic efficacy, response prediction and dose-response relations of treatment with metformin and sulfonylurea, alone and in primary combination. Diabet Med. 1994; 11:953-60.
14. Giugliano D, Quatraro A, Consoli G et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993; 44:107-12.